PureTech Health plc

PureTech Health plc develops and commercializes biotechnology and pharmaceutical solutions in the United States. The company is advancing several therapeutic candidates. LYT-100 is in Phase 2 development for treating idiopathic pulmonary fibrosis (IPF). LYT-200, an IgG4 monoclonal antibody targeting galectin-9, is in Phase 1/2 development for solid tumors and hematological malignancies. PureTech Health also develops SPT-300, an oral allopregnanolone drug for anxious depression, and aims to deliver transformative medicines for psychiatric and neurological conditions. In addition to these programs, the company is developing hydrogels to enable oral administration of peptide therapeutics, which are currently in preclinical development. It is also working on oral therapies based on defined bacterial consortia, which are in Phase 3 clinical development. Another area of focus is engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Furthermore, PureTech Health is developing a voice-based technology platform designed to detect changes in voice sounds linked to health conditions such as depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.